QQQ   424.06 (-0.42%)
AAPL   167.20 (-0.48%)
MSFT   405.19 (-1.61%)
META   503.38 (+1.86%)
GOOGL   156.45 (+0.63%)
AMZN   179.55 (-0.95%)
TSLA   150.45 (-3.22%)
NVDA   849.20 (+1.05%)
AMD   154.94 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.96 (+0.20%)
T   16.31 (+1.18%)
F   12.05 (+0.08%)
MU   112.52 (-3.28%)
GE   153.77 (-1.22%)
CGC   7.87 (+21.26%)
DIS   112.76 (-0.16%)
AMC   2.93 (-1.68%)
PFE   25.38 (-0.16%)
PYPL   62.08 (-1.87%)
XOM   118.72 (+0.08%)
QQQ   424.06 (-0.42%)
AAPL   167.20 (-0.48%)
MSFT   405.19 (-1.61%)
META   503.38 (+1.86%)
GOOGL   156.45 (+0.63%)
AMZN   179.55 (-0.95%)
TSLA   150.45 (-3.22%)
NVDA   849.20 (+1.05%)
AMD   154.94 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.96 (+0.20%)
T   16.31 (+1.18%)
F   12.05 (+0.08%)
MU   112.52 (-3.28%)
GE   153.77 (-1.22%)
CGC   7.87 (+21.26%)
DIS   112.76 (-0.16%)
AMC   2.93 (-1.68%)
PFE   25.38 (-0.16%)
PYPL   62.08 (-1.87%)
XOM   118.72 (+0.08%)
QQQ   424.06 (-0.42%)
AAPL   167.20 (-0.48%)
MSFT   405.19 (-1.61%)
META   503.38 (+1.86%)
GOOGL   156.45 (+0.63%)
AMZN   179.55 (-0.95%)
TSLA   150.45 (-3.22%)
NVDA   849.20 (+1.05%)
AMD   154.94 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.96 (+0.20%)
T   16.31 (+1.18%)
F   12.05 (+0.08%)
MU   112.52 (-3.28%)
GE   153.77 (-1.22%)
CGC   7.87 (+21.26%)
DIS   112.76 (-0.16%)
AMC   2.93 (-1.68%)
PFE   25.38 (-0.16%)
PYPL   62.08 (-1.87%)
XOM   118.72 (+0.08%)
QQQ   424.06 (-0.42%)
AAPL   167.20 (-0.48%)
MSFT   405.19 (-1.61%)
META   503.38 (+1.86%)
GOOGL   156.45 (+0.63%)
AMZN   179.55 (-0.95%)
TSLA   150.45 (-3.22%)
NVDA   849.20 (+1.05%)
AMD   154.94 (+0.60%)
NIO   4.01 (+2.56%)
BABA   68.96 (+0.20%)
T   16.31 (+1.18%)
F   12.05 (+0.08%)
MU   112.52 (-3.28%)
GE   153.77 (-1.22%)
CGC   7.87 (+21.26%)
DIS   112.76 (-0.16%)
AMC   2.93 (-1.68%)
PFE   25.38 (-0.16%)
PYPL   62.08 (-1.87%)
XOM   118.72 (+0.08%)
NASDAQ:INCY

Incyte (INCY) Stock Price, News & Analysis

$52.75
+0.03 (+0.06%)
(As of 03:52 PM ET)
Today's Range
$52.26
$53.15
50-Day Range
$52.72
$61.00
52-Week Range
$50.27
$75.74
Volume
1.24 million shs
Average Volume
1.70 million shs
Market Capitalization
$11.84 billion
P/E Ratio
19.91
Dividend Yield
N/A
Price Target
$76.07

Incyte MarketRank™ Stock Analysis

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
44.8% Upside
$76.07 Price Target
Short Interest
Bearish
3.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.66
Upright™ Environmental Score
News Sentiment
0.75mentions of Incyte in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
25.00%
From $3.84 to $4.80 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.85 out of 5 stars

Medical Sector

27th out of 914 stocks

Commercial Physical Research Industry

2nd out of 11 stocks

INCY stock logo

About Incyte Stock (NASDAQ:INCY)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Stock Price History

INCY Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Incyte to Report First Quarter Financial Results
Public Markets Are the New Private Markets
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
5 Biotech Stocks with Huge Potential
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
4/18/2024
Next Earnings (Confirmed)
4/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,524
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$76.07
High Stock Price Target
$93.00
Low Stock Price Target
$64.00
Potential Upside/Downside
+44.8%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$597.60 million
Pretax Margin
22.57%

Debt

Sales & Book Value

Annual Sales
$3.70 billion
Cash Flow
$2.40 per share
Book Value
$23.16 per share

Miscellaneous

Free Float
185,234,000
Market Cap
$11.79 billion
Optionable
Optionable
Beta
0.65

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

INCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price target for 2024?

15 brokerages have issued twelve-month price targets for Incyte's stock. Their INCY share price targets range from $64.00 to $93.00. On average, they predict the company's share price to reach $76.07 in the next year. This suggests a possible upside of 44.8% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2024?

Incyte's stock was trading at $62.79 at the start of the year. Since then, INCY stock has decreased by 16.4% and is now trading at $52.52.
View the best growth stocks for 2024 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our INCY earnings forecast
.

How can I listen to Incyte's earnings call?

Incyte will be holding an earnings conference call on Tuesday, April 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745743".

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Tuesday, February, 13th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.15 by $0.09. The biopharmaceutical company earned $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Incyte had a trailing twelve-month return on equity of 12.56% and a net margin of 16.17%. The business's revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.44 earnings per share.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.69%), Grimes & Company Inc. (0.08%), Diversified Trust Co (0.02%), IMC Chicago LLC (0.00%), Fulton Bank N.A. (0.01%) and Hennion & Walsh Asset Management Inc. (0.01%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Maria E Pasquale, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INCY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners